A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia

BACKGROUND: Hyperuricemia is an independent risk factor in chronic kidney disease (CKD). Allopurinol and febuxostat are prescription medicines used to treat hyperuricemia but suffer side-effects. Earlier clinical study has shown that an aqueous extract of Terminalia bellerica (TBE), significantly re...

Descripción completa

Detalles Bibliográficos
Autores principales: Pingali, Usharani, Nutalapati, Chandrasekhar, Koilagundla, Niranjan, Taduri, Gangadhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493401/
https://www.ncbi.nlm.nih.gov/pubmed/32933504
http://dx.doi.org/10.1186/s12906-020-03071-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493401/
https://www.ncbi.nlm.nih.gov/pubmed/32933504
http://dx.doi.org/10.1186/s12906-020-03071-7

Ejemplares similares